Crossmark

Overexpression of TREM1 predicts poor prognosis and chemotherapy resistance in Egyptian acute myeloid leukemia associated with FLT3 internal tandem duplication and CD123 expression and stemness signatures

Crossref DOI link: https://doi.org/10.1007/s12672-026-05009-w

Published Online: 2026-05-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mansor, Shima Gafar

Elgamal, Rasha

Saleh, Mostafa F. Mohammed

Othman, Amira A. A. https://orcid.org/0000-0002-8191-0035
Nawar, Sarah M.
License Information

Text and Data Mining valid from 2026-05-14

Version of Record valid from 2026-05-16
More Information

Article History

Received: 10 December 2025

Accepted: 9 April 2026

First Online: 14 May 2026

Declarations

:

: The study protocol was approved by the Institutional Review Board (IRB) of South Egypt Cancer Institute, Assiut University, Egypt (IRB No: 18 2025 743). All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional research committee and with the 2013 revision of the Declaration of Helsinki and Good Clinical Practice guidelines. All methods were carried out in accordance with relevant guidelines and regulations. Informed written consent was obtained from all individual participants included in the study. For patients with impaired decision-making capacity, consent was obtained from legally authorized representatives in accordance with approved surrogate consent procedures.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below